Wednesday, September 30, 2026
← Back to archivePolicy
Policy•KFF•Sep 29, 2026
Early Medicaid Work Requirement Insights From Nebraska
background ▾
- •Nebraska's first-mover implementation demonstrates that 86-93% of Medicaid applicants and renewals can meet or qualify for exemptions from work requirements, suggesting substantial compliance feasibility but also identify significant coverage loss risk (7-14%) for non-compliant populations.
- •States will transition from self-declaration to documentation requirements in January 2028, creating a critical compliance inflection point that may increase denials and disenrollment as verification standards tighten.
- •Monitor January 2027 national implementation and January 2028 documentation transition for coverage loss patterns, health equity impacts, and potential litigation challenges to work requirement constitutionality and hardship exception adequacy.
Policy•STAT News•Sep 30, 2026
Opinion: America’s biotech race with China must be won at home
background ▾
- •China's biomedicine five-year plan aims for 25% of global first-in-class drug production by 2030, up from current rates where the U.S. produces medicines at 7x China's rate, signaling rapid competitive erosion
- •Blanket tariffs and broad export controls on biotech partnerships risk disrupting U.S. supply chains and strengthening Chinese independent capabilities rather than containing them, based on precedent from semiconductors and 5G
- •Watch for U.S. policy decisions on biotech export controls and drug ingredient tariffs; the debate between containment versus competitive strengthening will shape biotech competitiveness over the next 5-10 years
Policy•STAT News•Sep 30, 2026
Kratom and 7-OH should be regulated, experts agree. They’re split on how
background ▾
- •DEA proposed Schedule I classification for 7-OH above a potency threshold as of July 2025, with finalization timeline uncertain after extended comment period through September 10
- •Addiction experts warn that Schedule I designation, while politically favored, creates risks for dependent users (withdrawal, prosecution) and may trigger regulatory whack-a-mole with new synthetic variants while restricting research
- •State and local jurisdictions are moving ahead with emergency bans on 7-OH and kratom pending federal action, signaling regulatory fragmentation and urgency around public health events (University of Mississippi student deaths)
American Kratom AssociationShatterproofkratom7-hydroxymitragyninemitragynine
→ Read original articlePolicy•KFF•Sep 29, 2026
Americans’ Challenges with Health Care Costs
background ▾
- •Healthcare cost anxiety remains the top financial worry for American adults (62% very or somewhat worried), surpassing concerns about housing, food, utilities, and transportation
Policy•Fierce Biotech•Sep 29, 2026
Canadian $5M accelerated clinical trial program cuts start-up to 45 days
background ▾
- •Ontario's QuickSTART program targets 45-day trial activation versus current 6-10 month timelines, with pilot data showing 20-day achievement at a single center
- •The $5 million provincial investment and participation from AstraZeneca and Roche signals commitment from both government and major pharma sponsors to address trial start-up inefficiency
- •Watch for adoption rates across Ontario's 180+ research sites and whether the accelerated timeline can be sustained without compromising regulatory/ethics review quality or whether other provinces/countries adopt similar models
AstraZenecaRoche CanadaClinical Trials Ontario
→ Read original articleMarket Access
Market Access•Endpoints News•Sep 29, 2026
SK pharmteco unveils $200M+ investment to expand CDMO capabilities
background ▾
- •SK pharmteco committing $200M+ to CDMO infrastructure expansion over five years
- •Investment addresses growing demand for outsourced manufacturing and development services in biotech
SK pharmteco
→ Read original articleMarket Access•Endpoints News•Sep 29, 2026
ARCH and Population Health return to China for new startup Somnivera, targeting sleep
background ▾
- •ARCH and Population Health are establishing Somnivera as a new sleep disorder-focused biotech with Chinese market presence
ARCHPopulation HealthSomnivera
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Sep 30, 2026
Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody
background ▾
- •Daxdilimab achieved a clinically meaningful 6-point CLASI-A reduction (50% improvement) at the lower dose, with 61.7% of patients reaching ≥50% reduction versus 23.7% placebo; both doses met all primary and secondary endpoints.
- •Excellent safety profile with no serious adverse events or deaths; one discontinuation due to arthralgia; clean tolerability strengthens regulatory pathway prospects.
- •Amgen is advancing daxdilimab to registration for discoid lupus and must demonstrate whether success in this skin-limited indication translates to broader systemic lupus applications, especially given prior SLE failure and the competitive landscape.
AmgenHorizon Therapeuticsdaxdilimab
→ Read original articleClinical Trials•Fierce Biotech•Sep 30, 2026
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
background ▾
- •Retatrutide achieved 34.9% ≥25% body weight loss versus tirzepatide's 34% ≥20% weight loss, establishing a new efficacy bar for GLP-1/GIP/glucagon triple agonists in obesity.
- •The drug demonstrated weaker glycemic control than tirzepatide (39–40% vs 55% achieving A1C <5.7%), suggesting differential benefit by indication—obesity vs. type 2 diabetes.
- •FDA approval filing expected Q1 2025; monitor for approval timeline and assess competitive landscape as rival triple-G programs (Hengrui/Kailera) advance toward clinical readouts.
Eli LillyHengrui PharmaKailera TherapeuticsretatrutidetirzepatideMounjaro
→ Read original articleClinical Trials•Fierce Biotech•Sep 29, 2026
uniQure stock crashes as Huntington’s gene therapy data weaken
background ▾
- •Primary endpoint (cUHDRS) weakened from 75% to 44% slowing at month 48 and lost statistical significance, but secondary endpoint (TFC) remained consistent at ~61% slowing, potentially supporting regulatory pathway
- •External control cohort has substantial methodological limitations (>50% missing data, healthier population bias after dropouts) that management and analysts argue underestimate treatment benefit, creating uncertainty about true efficacy signal
- •FDA's willingness to accept month 36 data for accelerated approval despite month 48 deterioration is critical to watch; if FDA re-analyzes with updated data, approval likelihood decreases materially
uniQureAMT-130
→ Read original articleClinical Trials•Fierce Biotech•Sep 30, 2026
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal program
background ▾
- •Petrelintide demonstrated optimal efficacy at the 5 mg dose (9.8% weight loss at Week 28, primary endpoint) with a clear plateau above that dose level, establishing the likely pivotal dose for phase 3 development
- •The drug's tolerability advantage—particularly lower rates of vomiting and diarrhea versus placebo—may differentiate it in a crowded GLP-1 market and support use as first-line monotherapy rather than combination therapy
- •Phase 3 initiation across three patient populations (obesity, obesity+T2D, obesity+CVD) begins immediately; late 2028 primary completion dates will determine whether this $1.65B acquisition delivers competitive returns against established and pipeline competitors
RocheZealand PharmaEli Lillypetrelintideeloralintide
→ Read original articleClinical Trials•STAT News•Sep 30, 2026
Opinion: STAT+: What to think about those mice with half-human brains
background ▾
- •Stanford researchers successfully generated mice with human cortical cells, a breakthrough in basic neuroscience research published in Nature